Identification and Investigation of Immunological Drug Response Mechanisms in Glioblastoma
Glioblastoma is a devastating form of adult brain cancer with 5% five-year survival rate, whichTemozolomide is the only available treatment option for patients. However, immunotherapy could serve as an alternative to bypass this problem. We robustly analyze the pMHC both in vitro and in vivo to identify targetable antigens using mass spectrometry. Underlying mechanism behind such overexpression will be investigated and validated for future development of combination immunotherapy.